Rationale and design of the cangrelor versus standard therapy to achieve optimal management of platelet inhibition PHOENIX trial

Sergio Leonardi, Kenneth W. Mahaffey, Harvey D. White, C. Michael Gibson, Gregg W. Stone, Gabriel W. Steg, Christian W. Hamm, Matthew J. Price, Meredith Todd, Markus Dietrich, Dianne Gallup, Tiepu Liu, Simona Skerjanec, Robert A. Harrington, Deepak L. Bhatt

Research output: Contribution to journalArticle

Abstract

Background: Despite robust efficacy in the reduction of ischemic events in patients who require percutaneous coronary intervention (PCI), current P2Y 12 inhibitors have limitations. In particular, they require hours to be effective, and they can only be administered orally. Cangrelor is an intravenous, potent, and reversible P2Y12 inhibitor with fast onset and offset of action. We designed CHAMPION PHOENIX to evaluate the efficacy and safety of cangrelor in patients with atherosclerosis undergoing PCI. Trial Design: The CHAMPION PHOENIX is a randomized, double-blind, double-dummy, superiority trial comparing cangrelor with clopidogrel standard of care in approximately 10,900 patients who have not previously received a P2Y 12 inhibitor and who require PCI, including patients with stable angina and with acute coronary syndromes (with or without ST-segment elevation). The primary objective of the study is to demonstrate that cangrelor will reduce the incidence of the composite of death, myocardial infarction (MI), ischemia-driven revascularization, or stent thrombosis in the 48 hours after randomization compared with clopidogrel without excessive periprocedural bleeding. The key secondary objective is to demonstrate that cangrelor will reduce the incidence of stent thrombosis. Myocardial infarction will be defined according to the universal MI definition, adapting the definition of PCI-related (type 4a) MI. Bleeding will be assessed according to the thrombolysis in myocardial infarction, GUSTO, and Bleeding Academic Research Consortium (BARC) scales. Conclusion: The CHAMPION PHOENIX may establish the role of cangrelor in the care of patients who require PCI across the spectrum of stable and unstable coronary diseases in the setting of current treatment strategies.

Original languageEnglish
JournalAmerican Heart Journal
Volume163
Issue number5
DOIs
Publication statusPublished - May 2012

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Rationale and design of the cangrelor versus standard therapy to achieve optimal management of platelet inhibition PHOENIX trial'. Together they form a unique fingerprint.

  • Cite this

    Leonardi, S., Mahaffey, K. W., White, H. D., Gibson, C. M., Stone, G. W., Steg, G. W., Hamm, C. W., Price, M. J., Todd, M., Dietrich, M., Gallup, D., Liu, T., Skerjanec, S., Harrington, R. A., & Bhatt, D. L. (2012). Rationale and design of the cangrelor versus standard therapy to achieve optimal management of platelet inhibition PHOENIX trial. American Heart Journal, 163(5). https://doi.org/10.1016/j.ahj.2012.02.018